scholarly article | Q13442814 |
P50 | author | Riad Salem | Q45736667 |
Zeeshan Butt | Q57072378 | ||
David Cella | Q62568473 | ||
P2093 | author name string | Laura Kulik | |
Daniel Ganger | |||
Ahsun Riaz | |||
Talia Baker | |||
Khairuddin Memon | |||
Michael Vouche | |||
Rohi Atassi | |||
Ryan Hickey | |||
Robert Lewandowski | |||
Michael M. Abecassis | |||
Al B. Benson | |||
James L. Burns | |||
Margaret Gilbertsen | |||
Mary F. Mulcahy | |||
P433 | issue | 10 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | quality of life | Q13100823 |
hepatocellular carcinoma | Q1148337 | ||
P304 | page(s) | 1358-1365.e1 | |
P577 | publication date | 2013-10-01 | |
P1433 | published in | Clinical Gastroenterology and Hepatology | Q5133759 |
P1476 | title | Increased Quality of Life Among Hepatocellular Carcinoma Patients Treated With Radioembolization, Compared With Chemoembolization | |
P478 | volume | 11 |
Q38465831 | (90)Y-glass microspheres for hepatic neoplasia |
Q59783545 | Association of PI3K Pathway Mutations with Early Positron-Emission Tomography/CT Imaging Response after Radioembolization for Breast Cancer Liver Metastases: Results of a Single-Center Retrospective Pilot Study |
Q26744307 | Current status of transarterial radioembolization |
Q98289959 | Epidemiologic, humanistic and economic burden of hepatocellular carcinoma in the USA: a systematic literature review |
Q41108851 | FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib. |
Q57756376 | Hepatocellular carcinoma |
Q61804598 | History and Evolution of Yttrium-90 Radioembolization for Hepatocellular Carcinoma |
Q38283692 | How does selective internal radiation therapy compare with and/or complement other liver-directed therapies |
Q38984450 | In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization? |
Q47573685 | Incorporating Quality of Life Metrics in Interventional Oncology Practice |
Q47384456 | Institutional Decision to Adopt Y90 as Primary Treatment for HCC Informed by a 1,000-patient 15-year Experience. |
Q38149993 | Intraarterial therapies for primary liver cancer: state of the art. |
Q94951977 | Liver Transplantation Following Yttrium-90 Radioembolization: 15-year Experience in 207-Patient Cohort |
Q49627939 | Liver-Directed Therapies for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma |
Q38686790 | Locoregional and systemic therapy for hepatocellular carcinoma |
Q87664325 | Management of hepatocellular carcinoma |
Q53216812 | Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus 90Y-radioembolization for hepatocellular carcinoma. |
Q38904263 | New concepts in embolotherapy of HCC. |
Q35128190 | Outcome of transarterial chemoembolization-based multi-modal treatment in patients with unresectable hepatocellular carcinoma |
Q37611108 | Patient-reported outcomes in liver transplant recipients with hepatocellular carcinoma |
Q48058236 | Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma |
Q90746927 | Position 2: Transarterial Radioembolization Should Be the Primary Locoregional Therapy for Unresectable Hepatocellular Carcinoma |
Q48049674 | Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study |
Q47556433 | Prospective longitudinal quality of life and survival outcomes in patients with advanced infiltrative hepatocellular carcinoma and portal vein thrombosis treated with Yttrium-90 radioembolization |
Q26753024 | Quality of Life in Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization |
Q90214924 | Quality of life in patients undergoing repetitive TACE for the treatment of intermediate stage HCC |
Q33872976 | Radioembolization for the treatment of hepatocellular carcinoma |
Q93377794 | Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis of randomized trials |
Q36062588 | Radioembolization with Yttrium-90 microspheres for patients with unresectable hepatocellular carcinoma |
Q27023616 | Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: Role and perspectives |
Q35164855 | Randomized comparison of selective internal radiotherapy (SIRT) versus drug-eluting bead transarterial chemoembolization (DEB-TACE) for the treatment of hepatocellular carcinoma. |
Q42378410 | Reactive oxygen species dependent phosphorylation of the liver kinase B1/AMP activated protein kinase/ acetyl-CoA carboxylase signaling is critically involved in apoptotic effect of lambertianic acid in hepatocellular carcinoma cells |
Q34045215 | Selective internal radiotherapy (SIRT) versus transarterial chemoembolization (TACE) for the treatment of intrahepatic cholangiocellular carcinoma (CCC): study protocol for a randomized controlled trial. |
Q27007847 | Systematic review of catheter-based intra-arterial therapies in hepatocellular carcinoma: state of the art and future directions |
Q32173610 | Systematic review of patient reported quality of life following stereotactic ablative radiotherapy for primary and metastatic liver cancer. |
Q26753089 | Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma |
Q38488732 | Transarterial approaches to primary and secondary hepatic malignancies. |
Q34702094 | Transarterial embolization therapies for the treatment of hepatocellular carcinoma: CEPO review and clinical recommendations |
Q26852174 | Transarterial radioembolization using yttrium-90 microspheres in the treatment of hepatocellular carcinoma: a review on clinical utility and developments |
Q33935237 | Transcatheter arterial chemoembolization for intermediate-stage hepatocellular carcinoma: clinical outcome and safety in elderly patients |
Q95282127 | Trial Design and Endpoints in hepatocellular carcinoma: AASLD Consensus Conference |
Q30248206 | Unresectable Hepatocellular Carcinoma: Radioembolization Versus Chemoembolization: A Systematic Review and Meta-analysis. |
Q38626594 | Value of quality of life analysis in liver cancer: A clinician's perspective |
Q36268905 | Yttrium-90 Radioembolization of Hepatocellular Carcinoma-Performance, Technical Advances, and Future Concepts |
Q26743603 | Yttrium-90 Selective Internal Radiation Therapy with Glass Microspheres for Hepatocellular Carcinoma: Current and Updated Literature Review |
Q35631304 | Yttrium-90 microsphere radioembolization for hepatocellular carcinoma |
Q36482781 | Yttrium-90 radioembolization stops progression of targeted breast cancer liver metastases after failed chemotherapy. |
Q58804965 | Yttrium-90 transarterial radioembolization versus conventional transarterial chemoembolization for patients with hepatocellular carcinoma: a systematic review and meta-analysis |
Search more.